Strategies for Synthesizing and Enhancing the Immune Response of Cancer Vaccines Based on MUC1 Glycopeptide Antigens

被引：9

作者：

Yin, Lixin ^{[1
]}

Zhou, Yang ^{[1
]}

Hong, Sheng ^{[1
]}

Ding, Feiqing ^{[1
]}

Cai, Hui ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen Campus,66 Gongchang Lu, Shenzhen 518107, Peoples R China

来源：

CHEMBIOCHEM | 2023年 / 24卷 / 10期

基金：

中国国家自然科学基金;

关键词：

cancer vaccine; Glycopeptide synthesis; MUC1; multicomponent; multivalent; SYNTHETIC ANTITUMOR VACCINES; TUMOR-ASSOCIATED MUCIN; T-CELL EPITOPES; IMMUNOLOGICAL EVALUATION; CONFORMATIONAL-ANALYSIS; DOUBLE-BLIND; NANOPARTICLES; GLYCOSYLATION; ADJUVANT; PEPTIDE;

D O I：

10.1002/cbic.202200805

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer vaccines are based on a vaccinology strategy whereby the patient's immune system is harnessed to induce a specific immune response to kill cancer cells and comprises two categories: prophylactic and therapeutic. Glycoprotein mucin 1 (MUC1), which is overexpressed and poorly glycosylated on cancer cells, is one of the most promising candidates for the development of new cancer vaccines. However, it should be noted that mucin-like glycopeptides are poorly immunogenic and unable to elicit effective and long-lasting immune responses. Therefore, MUC1-derived tumor antigens need to be conjugated with immune activators. This review focuses on the synthesis of MUC1 glycopeptides, provides an overview of recently advanced designs of vaccines based on MUC1, and compares the advantages and disadvantages of the various strategies devised to date.

引用

页数：16

共 131 条

[1] Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist [J].

Abdel-Aal, Abu-Baker M. ;

Lakshminarayanan, Vani ;

Thompson, Pamela ;

Supekar, Nitin ;

Bradley, Judy M. ;

Wolfert, Margreet A. ;

Cohen, Peter A. ;

Gendler, Sandra J. ;

Boons, Geert-Jan .

CHEMBIOCHEM, 2014, 15 (10) :1508-1513

[2] Design of Fully Synthetic, Self-Adjuvanting Vaccine Incorporating the Tumor-Associated Carbohydrate Tn Antigen and Lipoamino Acid-Based Toll-like Receptor 2 Ligand [J].

Abdel-Aal, Abu-Baker M. ;

El-Naggar, Dina ;

Zaman, Mehfuz ;

Batzloff, Michael ;

Toth, Istvan .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (15) :6968-6974

[3] MUC1 as a target antigen for cancer immunotherapy [J].

Acres, B ;

Limacher, JM .

EXPERT REVIEW OF VACCINES, 2005, 4 (04) :493-502

[4]

[Anonymous], 2001, ANGEW CHEM, V113, P379

[5]

[Anonymous], 2013, ANGEW CHEM, V125, P6222

[6]

[Anonymous], 2005, ANGEW CHEM, V117, P7803

[7]

[Anonymous], 2010, ANGEW CHEM, V122, P3772

[8]

[Anonymous], 2013, ANGEW CHEM, V125, P10846

[9]

[Anonymous], 2012, ANGEW CHEM, V124, P1751

[10]

[Anonymous], 2014, ANGEW CHEM, V126, P12111

← 1 2 3 4 5 6 7 8 9 10 →